NEW MEMBER CSL Behring joins FoCUS “CSL Behring strengthens our consortium’s perspectives on how to achieve patient impact with cutting-edge therapies,” said Gigi Hirsch, MD, executive director of NEWDIGS. “The … Read More
CSL Behring joins NEWDIGS FoCUS Project
Collaboration to improve accessibility and sustainability of new cell and gene therapiesThursday, May 27, 2021 Global biotherapeutic leader CSL Behring has joined the Massachusetts Institute of Technology Center for Biomedical Innovation’s New … Read More
Paying for Cures Self-Insured Employers workshop in June
Explore the impact of cell and gene therapies on your health benefit plans, survey the risks, and learn about solutions. Durable, potentially curative therapies for genetic disorders and cancer have … Read More
FoCUS Monthly Recap: March 2021
NEW RESEARCH Payer perspectives on outcomes tracking for value-based payment arrangements (VBPs) With the new CMS rule changing Medicaid Best Price reporting to encourage VBPs, many options are available for … Read More
Payer perspectives on outcomes tracking for value-based payment arrangements (VBPs)
Share the researchWith the new CMS rule changing Medicaid Best Price reporting to encourage VBPs, many options are available for which healthcare system players will collect, protect and adjudicate the … Read More
Tsega Meshesha, MS joins as FoCUS Program Manager
Tsega Meshesha, MS is a public health research specialist who designs evidence-based solutions to improve health outcomes. Having worked both domestically and internationally, she prides herself on being a trusted client … Read More
The resource navigation challenges for patients and caregivers
Share the researchWhile the problem of finding system-wide, implementable precision financing models for curative and durable therapies involves all stakeholders, patients and caregivers are directly affected by many different elements … Read More
FoCUS Monthly Recap: January 2021
RESEARCH BRIEF Resource navigation challenges for patients and caregivers While the problem of finding system-wide, implementable precision financing models for curative and durable therapies involves all stakeholders, patients and caregivers … Read More
FoCUS Monthly Recap: December 2020
IN THE MEDIAMark Trusheim coauthored the article “Market access of gene therapies across Europe, USA, and Canada: challenges, trends, and solutions” published in Science Direct: Drug Discovery Today, November 24, 2020. This review … Read More
FoCUS Monthly Recap: October 2020
WHITE PAPER Warranty Model: A potential precision financing solution for durable cell and gene therapies Durable cell and gene therapies are poised for rapid growth—posing transformative benefits for patients and … Read More